PROTOKINETIX, INCORPORATED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.0105 USD | -4.55% |
|
-30.00% | -44.74% |
| 05-15 | ProtoKinetix, Incorporated Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| 03-29 | ProtoKinetix, Incorporated announced a financing transaction | CI |
| Sales 2022 | - | Sales 2023 | - | Capitalization | 6.58M 519M |
|---|---|---|---|---|---|
| Net income 2022 | -1M -78.83M | Net income 2023 | - 0 | EV / Sales 2022 | - |
| Net cash position 2022 | 25.55K 2.01M | Net cash position 2023 | 20.41K 1.61M | EV / Sales 2023 | - |
| P/E ratio 2022 |
-4.29
x | P/E ratio 2023 |
-1.9
x | Employees | 5 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 58.75% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | -4.55% | ||
| 1 week | -30.00% | ||
| Current month | -26.06% | ||
| 1 month | -29.53% | ||
| 3 months | -47.24% | ||
| 6 months | -54.35% | ||
| Current year | -44.74% |
1 week
0.01
0.02
1 month
0.010.02
Current year
0.010.02
1 year
0.010.03
3 years
0.010.17
5 years
0.010.29
10 years
0.010.32
| Managers | Title | Age | Since |
|---|---|---|---|
Clarence Smith
CEO | Chief Executive Officer | 60 | 31/05/14 |
Michael Guzzetta
DFI | Director of Finance/CFO | 66 | 13/11/17 |
Victoria Bantz
LAW | General Counsel | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Clarence Smith
CEO | Chief Executive Officer | 60 | 31/05/14 |
Edward McDonough
BRD | Director/Board Member | 71 | 30/06/15 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 18/06/24 | 0.0105 | -4.55% | 302,046 |
| 17/06/24 | 0.011 | -0.90% | 668,100 |
| 14/06/24 | 0.0111 | -14.62% | 364,600 |
| 13/06/24 | 0.013 | -13.33% | 53,650 |
Delayed Quote OTC Markets, June 18, 2024 at 06:18 pm
More quotes
ProtoKinetix, Incorporated is a research and development stage biotechnology company. The Company is focused on scientific medical research of Anti-Freeze Glycoproteins (AFGPs) or anti-aging glycoproteins. The Companyâs anti-aging glycopeptide is for ophthalmology, dermatology, transplant support and biomanufacturing. The commercial applications for AAGPs include various health care solutions. In a clinical setting, AAGP is showing its ability to protect cells from inflammation, repair and replace damaged cells and improve cell survivability over time. The Company has not developed a commercially viable product and has not generated any revenue.
| 1st Jan change | Capi. | |
|---|---|---|
| -44.74% | 3.71M | |
| +34.01% | 51.07B | |
| -8.02% | 38.78B | |
| +34.66% | 38.61B | |
| -8.98% | 27.32B | |
| +12.56% | 26.35B | |
| -19.62% | 19.46B | |
| +39.18% | 13.58B | |
| +31.47% | 12.46B | |
| -3.40% | 11.75B |
- Stock Market
- Equities
- PKTX Stock
